A study to assess ability of the International mRCC Database Consortium criteria to risk stratify across use of novel first line immunotherapy combinations and older first and second line treatments
Latest Information Update: 19 Jun 2020
At a glance
- Drugs Axitinib (Primary) ; Cabozantinib (Primary) ; Everolimus (Primary) ; Lenvatinib (Primary) ; Nivolumab (Primary) ; Pazopanib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 19 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology